神奈川県立がんセンター臨床研究所
お問い合わせ

Cancer Prevention and Control Division

当研究所について
研究活動
基礎的技術支援コアセンター
共同研究したい
学生として研究したい
研究員として働きたい
情報セキュリティポリシー
公的研究費の適正管理
交通案内
お問い合わせ
病院サイトはこちら

Cancer Prevention and Control Division

The onset of an aging society in Japan is forcing considerable changes in health and medical care. The Cancer Prevention and Control Division studies the association between social systems and technical innovation in the field of health and medical care, i.e. health innovation. We aim to pursue new challenges, fusing science, technology, and industrial policy with health and medical care, unrestricted by the conventional frameworks of epidemiology and prevention.
Our Division has been responsible for the registration of cancer in the Kanagawa prefecture for over 30 years. Moreover, in 2016, we started “the Kanagawa ME-BYO prospective cohort study”, a large-scale genome cohort study. We draw on the epidemiological and public health fruits of research efforts like these to tackle new challenges as they rise to meet us.
Research activities are pursued in particularly close collaboration with the Kanagawa Prefecture, which has a Healthcare New Frontier policy and is promoting effective cancer counter measures, and with the Graduate School of Health Innovation, Kanagawa University of Human Services https://www.shi.kuhs.ac.jp/en/ , responsible for the upbringing of the next generation of innovators in health care and medicine (director Hiroto Narimatsu serves concurrently as a professor in the same School through a cross-appointment system).

Research Topics

Cancer Registration Activities

The division has been responsible for the registration of cancer in Kanagawa Prefecture since 1970. Currently, there is stored master data on more than a million cases, making this one of the largest databases in Japan. Registration of cancer in all of Japan started in 2016, and in the Kanagawa Prefecture we have constructed a system that continues in parallel with cancer registration for Japan as a whole, and regional cancer registration.

Cancer Screening Precision Management Activities

The precision of cancer screening (sensitivity and specificity) is calculated by cross-checking cancer registration and cancer screening data; it serves as an indicator of precision management. Activities started in 2019 as a collaborative study with the Yokohama Medical Association commissioned by Yokohama City. This is the first initiative in Japan that has taken on this challenge in large-scale municipalities.

Genome cohort study, “the Kanagawa ME-BYO prospective cohort study”

The purpose is to produce big data from comprehensive lifestyle and health check data, including genome information from the state of health, in order to clarify patient risk factors, and to use these insights in combatting pre-symptomatic disease (disease prevention). In 2016, a genome cohort was established in the western part of the prefecture collaborating in the Japanese Multi-Institutional Collaborative Cohort Study (J-MICC study). Surveys are proceeding with the object of recruiting 5000 people in the 5-year baseline survey period.
Director Narimatsu is acting as the principal investigator, and guest researcher Nakamura (Lecturer, Graduate School of Health Innovation, Kanagawa University of Human Services) is acting as the director of the cohort study office.
Analysis of the cohort data is also proceeding energetically in collaboration with J-MICC and the Tohoku Medical Megabank Organization.

Intervention Cohort Studies (ME-BYO and ME-RISE project)

These are advanced strategic initiatives tackling the evaluation and social implications of preventive medical interventions that use cutting-edge technology and take our genome cohort as their platform. With the support of those in charge of the Kanagawa Prefecture Healthcare New Frontier, together with private enterprise and academia, we were able to get the study partially underway in 2019.

  1. Health intervention with a patient risk prediction model as an indicator for intervention
    This is a prospective randomized intervention study, using the operations research method of data envelope analysis, to demonstrate whether it is possible to prevent the development of hypertension by early health intervention in selected patients with a high risk of developing hypertension. As a result, using the genome cohort data, our research team has discovered the possibility of health intervention in preventive treatment. This is being carried out as a collaborative study with the Kanagawa Prefectural Health and Welfare University School of Health Innovation and Takata Hospital, Takata-machi, Hitashiokitama-gun, Yamagata-ken.
  2. Program to develop a preventive care method using a healthcare robot
    This is a study directed to the development of an effective preventive care program for elderly people, assessed as frail or pre-frail, making use of the robot suit HAL (Cyberdyne Inc.) hip type. In 2019, a feasibility study with 20 subjects was started as a collaborative study with the Shonan Robocare Center (KK), Keio University, and Kanagawa Prefectural Health and Welfare University School of Health Innovation. In 2020, a controlled randomized study started. Cases are currently being enrolled.

Development of a Medical Intervention System Making Use of AI

Augmented intelligence (AI), which has undergone development in recent years, and is being put into practical use, is known to have various functions, including the use of chatbots to support simulations of Parkinson's disease and autism, etc.
In order to increase the efficiency of the screening of hereditary cancer patients and increase the number of subjects screened, and to offer genetic examination to more people, a screening chatbot is being developed in collaboration with the Kanagawa Cancer Center Genetic Examination Department and AIT KK, making use of IBM Watson®. Research directed towards producing a prototype, clinical application, and application to combatting pre-symptomatic illness, is in progress.

Examples of Applications (AIT website)

Research Achievement

2022年

  1. Haneda E, Sato A, Suganuma N, Sebata Y, Okamoto S, Toda S, Kohagura K, Matsubara Y, Sugawara Y, Yamanaka T, Yamashita T, Shimizu S, Narimatsu H. Efficacy of Clinical Guidelines in Identifying All Japanese Patients with Hereditary Breast and Ovarian Cancer. Int J Environ Res Public Health. 2022;19(10). Epub 20220519.  IF=4.61
  2. Kishi H, Watanabe K, Nakamura S, Taguchi H, Narimatsu H. Impact of nurses' roles and burden on burnout during the COVID-19 pandemic: multicenter cross-sectional survey. J Nurs Manag. 2022. Epub 20220428. IF=3.32
  3. Miyaji A, Watanabe K, Takano Y, Nakasho K, Nakamura S, Wang Y, Narimatsu H. A Privacy-Preserving Distributed Medical Data Integration Security System for Accuracy Assessment of Cancer Screening: Development Study of Novel Data Integration System. JMIR Med Inform. 2022;10(12):e38922. Epub 20221230. IF=3.2
  4. Saito Y, Nakamura S, Tanaka A, Watanabe R, Narimatsu H, Chung U-i. Evaluation of the validity and reliability of the 10-meter walk test using a smartphone application among Japanese older adults. Frontiers in Sports and Active Living. 2022;4:904924. Epub 20221004. IF=N/A
  5. Saito Y, Nakamura S, Tanaka A, Watanabe R, Narimatsu H, Chung UI. Checking the validity and reliability of the Japanese version of the Mini-Cog using a smartphone application. BMC Res Notes. 2022;15(1):222. Epub 20220625. IF=1.66.
  6. Sawaguchi E, Nakamura S, Watanabe K, Tsuno K, Ikegami H, Shinmura N, Saito Y, Narimatsu H. COVID-19-related stigma and its relationship with mental wellbeing: A cross-sectional analysis of a cohort study in Japan. Front Public Health. 2022;10:1010720. Epub 20220929. IF=6.46
  7. Takahashi K, Nakamura S, Watanabe K, Sakaguchi M, Narimatsu H. Availability of Financial and Medical Resources for Screening Providers and Its Impact on Cancer Screening Uptake and Intervention Programs. Int J Environ Res Public Health. 2022;19(18). Epub 20220912. IF=4.61
  8. Takumoto Y, Sasahara Y, T Murata, Narimatsu H, Akazawa M. Manabu A. Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan. Health Econ Rev. 2022;12(1):63. Epub 20221224. IF=1.75
  9. Kawakami R, Tanisawa K, Ito T, Usui C, Miyachi M, Torii S, Midorikawa T, Ishii K, Muraoka I, Suzuki K, Sakamoto S, Higuchi M, Oka K. Fat-Free Mass Index as a Surrogate Marker of Appendicular Skeletal Muscle Mass Index for Low Muscle Mass Screening in Sarcopenia. J Am Med Dir Assoc. 2022;23(12):1955-61 e3. Epub 20220928. IF=4.67
  10. Iwagami M, Goto A, Katagiri R, Sutoh Y, Koyanagi YN, Nakatochi M, Nakano S, Hanyuda A, Narita A, Shimizu A, Tanno K, Hozawa A, Kinoshita K, Oze I, Ito H, Yamaji T, Sawada N, Nakamura Y, Nakamura S, Kuriki K, Suzuki S, Hishida A, Kasugai Y, Imoto I, Suzuki M, Momozawa Y, Takeuchi K, Yamamoto M, Sasaki M, Matsuo K, Tsugane S, Wakai K, Iwasaki M. Blood Lipids and the Risk of Colorectal Cancer: Mendelian Randomization Analyses in the Japanese Consortium of Genetic Epidemiology Studies. Cancer Prev Res (Phila). 2022 Dec 1;15(12):827-836. IF=3.30
  11. Nakamura S, Fang X, Saito Y, Narimatsu H, Ota A, Ikezaki H, Shimanoe C, Tanaka K, Kubo Y, Tsukamoto M, Tamura T, Hishida A, Oze I, Koyanagi Y.N, Nakamura Y, Kusakabe M, Takezaki T, Nishimoto D, Suzuki S, Otani T, Kuriyama N, Matsui D, Kuriki K, Kadota A, Nakamura Y, Arisawa K, Katsuura-Kamano S, Nakatochi M, Momozawa Y, Kubo M, Takeuchi K, Wakai K. Effects of gene–lifestyle interactions on obesity based on a multi-locus risk score: A cross-sectional analysis. 2023 Feb 8;18(2): e0279169. IF=3.75
  12. Ryoko Katagiri, Atsushi Goto, Shiori Nakano, Masahiro Nakatochi, Yuriko N. Koyanagi, Masao Iwagami, Akiko Hanyuda, Taiki Yamaji, Norie Sawada, Yohko Nakamura, Sho Nakamura, Kiyonori Kuriki, Sadao Suzuki, Issei Imoto, Yukihide Momozawa, Isao Oze, Hidemi Ito, Shoichiro Tsugane, Kenji Wakai, Keitaro Matsuo, Motoki Iwasaki. Association of 25-hydroxyvitamin D with risk of overall , colorectal cancer among Japanese using A Mendelian randomization approach. Sci Rep (In press) IF=5.00
  13. Saito Y, Watanabe N, Suzuki N, Saito N, Narimatsu H, Takami H, Kameyama K, Yoshioka K, Masaki C, Akaishi J, Hames KY, Matsumoto M, Fukushita M, Yoshihara A, Okamura R, Tomoda C, Suzuki A, Matsuzu K, Kitagawa W, Nagahama M, Noh JY, Sugino K, Ito K. Role of Surgery in Patients with Stage IE Primary Thyroid MALT Lymphoma Staged by a Modified Classification System: The Tokyo Classification. Cancers (Basel). 2023;15(5). IF＝6.58

2021年

  1. Enomoto N, Nakamura S, Kanda S, Endo H, Yamada E, Kobayashi S, Kido M, Inoue R, Shimakura J, Narimatsu H. Efficacy of Additional Intervention to the Specific Health Guidance in Japan: The Takahata GENKI Project. Risk Manag Healthc Policy. 2021;14:3935-43. Epub 20210921. pubdate 2021 Sep IF 3.20
  2. Kanouchi K, Narimatsu H, Shirata T, Morikane K. Diagnostic analysis of lupus anticoagulant using clot waveform analysis in activated partial thromboplastin time prolonged cases: A retrospective analysis. Health Sci Rep. 2021;4(2):e258. Epub 20210312. pubdate 2021 Jun IF 1.56
  3. Kobayashi S, Koizume S, Takahashi T, Ueno M, Oishi R, Nagashima S, Sano Y, Fukushima T, Tezuka S, Morimoto M, Nakamura S, Narimatsu H, Ruf W, Miyagi Y. Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer. Cancer Sci. 2021;112(11):4679-91. Epub 20210830. pubdate 2021 Nov IF 6.72
  4. Okamura Y, Boku N, Ghaneh P, Greenhalf W, Yasukawa S, Narimatsu H, Fukutomi A, Konishi M, Morinaga S, Toyama H, Maeda A, Shimizu Y, Nakamori S, Sata N, Yamakita K, Takahashi A, Takayama W, Yamaguchi R, Tomikawa M, Yanagisawa A, Neoptolemos JP, Uesaka K. Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical outcomes of adjuvant chemotherapy for pancreatic cancer: A collaborative study from the JASPAC 01 trial. Cancer Rep (Hoboken). 2021:e1507. Epub 20210729. pubdate 2021 Jul 29 IF 0.77
  5. Suganuma N, Kawachi K, Yamashita T, Yamanaka T, Sugawara Y, Matsubara Y, Yamazaki H, Kohagura K, Toda S, Okamoto S, Yoshida T, Rino Y, Masuda M, Narimatsu H, Fujita H, Yoshioka E, Yokose T, Furuta K, Miyagi Y. Quality Control of Breast Cancer Surgery Samples: Introducing Time Stamp Checking. Biopreserv Biobank. 2021;19(5):369-75. Epub 20210429. pubdate 2021 Oct IF 2.30
  6. Suzuki H, Narimatsu H, Nakane M, Sadahiro M, Kawamae K. Perioperative presepsin as a potential early predictor for postoperative infectious complications in cardiac surgery. Anaesthesiology Intensive Therapy. 2021;53(3):215-22. pubdate 2021 IF 0.84
  7. Takumoto Y, Sasahara Y, Narimatsu H, Akazawa M. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis. JAMA Netw Open. 2022;5(1):e2145515. Epub 20220104. pubdate 2022 Jan 4 IF 8.48
  8. Suganuma N, Kawachi K Yamashita T, Yamanaka T, Sugawara Y, Matsubara Y, Yamazaki Y, Kohagura K, Toda S, Okamoto S, Yoshida T, Rino Y, Masuda M, Narimatsu H, Fujita H, Yoshioka E, Yokose T, Furuta K, Miyagi Y. Quality Control of Breast Cancer Surgery Samples - Introducing Time Stamp Checking Biopreserv Biobank, 2021 in press IF=2.0

2020年

  1. Narimatsu H, Sakaguchi M, Nakamura S, Katayama K. Future Patient Incidence in Hemato-Oncology: A Study Using Data from Cancer Registries in Japan. Risk management and healthcare policy. 2020;13:2407-14. Epub 2020/11/12. IF 2.429
  2. Sugawara Y, Murakami M, Narimatsu H. Use of Social Media by Hospitals and Clinics in Japan: Descriptive Study. JMIR Med Inform. 2020;8(11):e18666. Epub 2020/11/28. IF 2.58
  3. Takeuchi K, Naito M, Kawai S, Tsukamoto M, Kadomatsu Y, Kubo Y, Okada R, Nagayoshi M, Tamura T, Hishida A, Nakatochi M, Sasakabe T, Hashimoto S, Eguchi H, Momozawa Y, Ikezaki H, Murata M, Furusyo N, Tanaka K, Hara M, Nishida Y, Matsuo K, Ito H, Oze I, Mikami H, Nakamura Y, Kusakabe M, Takezaki T, Ibusuki R, Shimoshikiryo I, Suzuki S, Nishiyama T, Watanabe M, Koyama T, Ozaki E, Watanabe I, Kuriki K, Kita Y, Ueshima H, Matsui K, Arisawa K, Uemura H, Katsuura-Kamano S, Nakamura S, Narimatsu H, Hamajima N, Tanaka H, Wakai K. Study profile of the Japan Multi-institutional Collaborative Cohort (J-MICC) Study. J Epidemiol. 2020. Epub 2020/09/24. IF 3.691
  4. Watanabe K, Katayama K, Yoshioka T, Narimatsu H. Impact of individual background on the unmet needs of cancer survivors and caregivers - a mixed-methods analysis. BMC Cancer. 2020;20(1):263. Epub 2020/04/02. IF 3.15
  5. Yasui M, Sakaguchi M, Jikuya R, Tsutsumi S, Tatenuma T, Noguchi G, Umemoto S, Katayama K, Narimatsu H, Uemura H, Kishida T. Comparative effectiveness of surgery and radiotherapy for survival of patients with clinically localized prostate cancer: A population-based coarsened exact matching retrospective cohort study. Oncol Lett. 2020;20(5):150. Epub 2020/09/17. IF 2.31
  6. Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Ohgi K, Sasaki K, Narimatsu H, Uesaka K. The prognostic roles of the prognostic nutritional index in patients with intraductal papillary mucinous neoplasm. Sci Rep. 2021;11(1):568. Epub 2021/01/14. IF 4.00
  7. Sato A, Haneda E, Suganuma N, Narimatsu H. Preliminary Screening for Hereditary Breast and Ovarian Cancer Using a Chatbot Augmented Intelligence Genetic Counselor: Development and Feasibility Study. JMIR Form Res. 2021;5(2):e25184. Epub 2021/02/06. IF なし

Staff

　

※メールアドレスの[at]は＠に直してご送信ください。

  • 成松 宏人なりまつ ひろと

    役職 部長
    Eメール narimatsu.0750f [at] kanagawa-pho.jp
    専門 臨床遺伝学、臨床疫学（博士（医学））

  • 渡邉 要わたなべ かなめ

    役職 任期付研究員
    Eメール watanabe.5f90l [at] kanagawa-pho.jp
    専門 臨床腫瘍学、臨床疫学（博士（医学））

  • CHEI CHOY LYEチェイ チョイ ライ

    役職 任期付研究員
    Eメール clchei.7g20n[at]kanagawa-pho.jp
    専門 疫学、予防医学（博士（医科学））

  • 今井 香織いまい かおり

    役職 主任主事
    Eメール imai.3c90h [at] kanagawa-pho.jp

  • 髙木 愛たかぎ あい

    役職 臨時主事
    Eメール takagi.4b30j [at] kanagawa-pho.jp

  • 西亀 志保にしき しほ

    役職 契約職員（神奈川県立保健福祉大学ヘルスイノベーション研究科より派遣）
    Eメール nishiki-n5g[at]kuhs.ac.jp

  • 窪山 あや子くぼやま あやこ

    役職 事務補助員
    Eメール kuboyama.dl90m [at] kanagawa-pho.jp

  • 荻原 亨おぎはら とおる

    役職 事務補助員
    Eメール ogihara.cd80n[at]kanagawa-pho.jp

  • 夏井 佐代子なつい さよこ

    役職 事務補助員
    Eメール natsui.b220n [at] kanagawa-pho.jp

  • 高木 英明たかぎ ひであき

    役職 客員研究員 （筑波大学名誉教授）

  • 中村 翔なかむら しょう

    役職 客員研究員 （神奈川県立保健福祉大学ヘルスイノベーション研究科准教授）

  • 尾崎 章彦おざき あきひこ

    役職 客員研究員 （福島県立医科大学特任教授／ときわ会常磐病院乳腺甲状腺外科）

  • 菅原 祐也すがわら ゆうや

    役職 研修生 （山形大学医学部メディカルサイエンス推進研究所情報基盤センター、RIセンター（兼）教務職員）

  • 吉田 達哉よしだ たつや

    役職 研修生 （済生会横浜市南部病院外科兼乳腺センター）

  • 神田 悟かんだ さとる

    役職 研修生 （山形大学医学部臨床腫瘍学講座・附属病院腫瘍内科）

  • 高橋 鴻志たかはし こうし

    役職 研修生 （山形大学医学部付属病院　臨床腫瘍学講座／金山町立金山診療所所長）

  • 新村 直子しんむら なおこ

    役職 研修生 （一般社団法人ハイジアコミュニケーション　代表理事・理事長）

  • Tran Quyen Anチャン グエン アン

    役職 研修生　（神奈川県立保健福祉大学大学院ヘルスイノベーション研究科博士課程学生）

  • 齋藤 宏章さいとう ひろあき

    役職 研修生 （福島県立医科大学　医療法人社団茶畑会　相馬中央病院内科）

  • 岡本 真澄おかもと ますみ

    役職 研修生 （神奈川県立保健福祉大学イノベーション政策研究センター 研究員）

Contact

045-520-2222（代表）

受付時間 9:00～17:00（平日のみ）

お問い合わせ